FGF19 and metabolic dysfunction-associated steatohepatitis: NGM282, a newly engineered analog of FGF19 designed to avoid activation of the STAT3 pathway and thus likely reduce the tumorigenic potential of FGF19, showed a significant reduction in liver fat content in a phase II study with 82 MASH patients [1].